Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 9/20 | 0.58 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1185751 | 0.93 | HTR7 (0.53) | HTR7HTR1A | |
| SCHEMBL1185143 | 0.84 | HTR7 (0.52) | HTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL1492353 | 0.82 | HTR7 (0.49) | HTR7HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1492422 | 0.82 | HTR7 (0.49) | HTR7HTR1AADRA1A | |
| SCHEMBL1492411 | 0.81 | HTR7 (0.48) | HTR7HTR1AADRA1A | |
| Fumaric Acid SCHEMBL1187325 | 0.79 | HTR7 (0.49) | HTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL1492377 | 0.78 | LMNA (0.44) | HTR7 | |
| SCHEMBL3648904 | 0.74 | LMNA (0.48) | HTR7 | |
| SCHEMBL20371571 | 0.72 | LMNA (0.46) | — | |
| SCHEMBL1185948 | 0.72 | TACR1 (0.54) | HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028490-A1 | 4-PHENYL-PIPERAZIN-1-YL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE IN-HIBITORS | NEUROSEARCH A/S (DK) | 2011-02-03 | — | — | US | claimed |
| EP-2238117-A1 | 4-PHENYL-PIPERAZIN-1-YL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-10-13 | — | — | EP | claimed |
| WO-2009092720-A1 | 4-PHENYL-PIPERAZIN-1-YL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-07-30 | — | — | WO | claimed |
| US-20110028490-A1 | 4-PHENYL-PIPERAZIN-1-YL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE IN-HIBITORS | NEUROSEARCH A/S (DK) | 2011-02-03 | — | — | US | disclosed |
| EP-2238117-A1 | 4-PHENYL-PIPERAZIN-1-YL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009092720-A1 | 4-PHENYL-PIPERAZIN-1-YL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028490-A1 | 4-PHENYL-PIPERAZIN-1-YL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE IN-HIBITORS | SLC18A2, SLC6A2, SLC18A3 | HTR7 104/4885HTR1A 13/4885ADRA1D 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.